Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George H Talbot

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|September 18, 2014
Dalbavancin or oritavancin for skin infectionsHelen W Boucher, George H Talbot, Michael W Dunne
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2015
Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of HealthGeorge H Talbot, John H Powers, Steven C Hoffmann, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2007
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsGeorge H Talbot, Dirk Thye, Anita Das, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2010
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusionsYigong Ge, M J Whitehouse, Ian Friedland, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United StatesYigong Ge, Donald Biek, George H Talbot, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2012
Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infectionsGeorge H Talbot, Tanya O'Neal, Anita F Das, et al.
Annals of Internal Medicine|December 29, 2016
The Fight Against Multidrug-Resistant BacteriaHelen W Boucher, Sara E Cosgrove, Edward Cox, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile InfectionLeah Kleinman, George H Talbot, Elke Hunsche, et al.
Drug Safety|December 31, 2015
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesMichael W Dunne, George H Talbot, Helen W Boucher, et al.
International Journal of Antimicrobial Agents|June 11, 2017
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time pointThomas M File, Paul B Eckburg, George H Talbot, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|September 18, 2014
Dalbavancin or oritavancin for skin infectionsHelen W Boucher, George H Talbot, Michael W Dunne
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2015
Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of HealthGeorge H Talbot, John H Powers, Steven C Hoffmann, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2007
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsGeorge H Talbot, Dirk Thye, Anita Das, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2010
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusionsYigong Ge, M J Whitehouse, Ian Friedland, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United StatesYigong Ge, Donald Biek, George H Talbot, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2012
Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infectionsGeorge H Talbot, Tanya O'Neal, Anita F Das, et al.
Annals of Internal Medicine|December 29, 2016
The Fight Against Multidrug-Resistant BacteriaHelen W Boucher, Sara E Cosgrove, Edward Cox, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile InfectionLeah Kleinman, George H Talbot, Elke Hunsche, et al.
Drug Safety|December 31, 2015
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesMichael W Dunne, George H Talbot, Helen W Boucher, et al.
International Journal of Antimicrobial Agents|June 11, 2017
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time pointThomas M File, Paul B Eckburg, George H Talbot, et al.
Pageof 5